A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer

Chenxue Jiang; Shuiyun Han; Wucheng Chen; Xiaozhen Ying; He Wu; Yaoyao Zhu; Guodong Shi; Xiaojiang Sun; Yaping Xu

doi:10.18632/oncotarget.23849

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer

Chenxue Jiang _, Shuiyun Han, Wucheng Chen, Xiaozhen Ying, He Wu, Yaoyao Zhu, Guodong Shi, Xiaojiang Sun and Yaping Xu

PDF | HTML | How to cite

Oncotarget. 2018; 9:12443-12451. https://doi.org/10.18632/oncotarget.23849

Metrics: PDF 1377 views | HTML 2605 views | ?

Abstract

Chenxue Jiang1,2,*, Shuiyun Han2,*, Wucheng Chen1,2, Xiaozhen Ying1,2, He Wu1,2, Yaoyao Zhu1,2, Guodong Shi2, Xiaojiang Sun2 and Yaping Xu1,2

1First Clinical Medical School, Wenzhou Medical University, Wenzhou, PR China

2Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, PR China

*These authors contributed equally to this work

Correspondence to:

Yaping Xu, email: [email protected]

Keywords: lung cancer; chemoradiation therapy; dose escalation; adaptive radiotherapy

Received: April 04, 2017 Accepted: October 26, 2017 Published: January 03, 2018

ABSTRACT

Background and purpose: This retrospective study aimed to investigate the feasibility of shrinking field radiotherapy during chemoradiotherapy in non-small cell lung cancer (NSCLC).

Patients and methods: Ninety-seven patients with stage III NSCLC who achieved a good response to chemoradiation were analyzed. Computed tomography was performed after 40-50 Gy dose radiation to evaluate curative effect. Patients in the shrinking field group underwent resimulation CT scans and shrinking field radiotherapy. Acute symptomatic irradiation-induced pneumonia (ASIP), progression patterns and survival were assessed.

Results: Of the 97 patients who achieved response after a median total dose of 60 Gy, fifty patients received shrinking field radiotherapy. The incidence of acute symptomatic irradiation-induced pneumonia tended to be lower for the shrinking field group (18.0% vs. 23.4%, P = 0.51). The rate of disease progression was significantly higher in the non-shrinking than shrinking field group (95.7% vs. 66.0%, P < 0.001). Compared to the non-shrinking field group, the shrinking field group had similar overall survival (30.0 vs. 30.0 months, P = 0.58) but significantly better median progression-free survival (14.0 vs. 11.0 months, P = 0.006).

Conclusions: Shrinking field radiotherapy during chemoradiotherapy in stage III non-small cell lung cancer seems safe with acceptable toxicities and relapse, and potentially spares normal tissues and enables dose escalation. Prospective trials are warranted.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23849

Publication Alerts

Post-Publication Promotion

Clinical Research Papers:

A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer

Abstract